scientific secretariat sede faculty segreteria ... · via dei cartari, 18 - 90133 palermo...
TRANSCRIPT
SEDEGrand Hotel Piazza Borsa
Via dei Cartari, 18 - 90133 Palermo
SEGRETERIA ORGANIZZATIVA
PLS Educational SrlVia della Mattonaia, 17 - 50121 FirenzeTel. 055 2462241 - Fax 055 2462270
E-mail: [email protected]
www.maki-adv.it
THANKS TO ALL THE SPONSORSFOR THEIR EDUCATIONAL
AND NO-CONDITIONING CONTRIBUTIONFOR THE CONGRESS REALIZATION
Safety of immunosuppressive treatment in the management of Inflammatory
II Congress
Bowel diseaseGrand Hotel Piazza Borsa Palermo9-10 dicembre 2016
SCIENTIFIC SECRETARIATAmbrogio Orlando
Claudio Romano
FACULTYMarina Aloi (Rome, Italy)
Alessandro Armuzzi (Rome, Italy)Livia Biancone (Rome, Italy)
Calogero Cammà (Palermo, Italy)Maria Cappello (Palermo, Italy)
Fabiana Castiglione (Naples, Italy)Michele Citrano (Palermo, Italy)Mario Cottone (Palermo, Italy)Antonio Craxì (Palermo, Italy)
Valeria Criscuoli (Palermo, Italy)Walter Fries (Messina, Italy)
Paolo Gionchetti (Bologna, Italy)David Laharie (Bordeaux, France)
Paolo Lionetti (Florence, Italy)Fabio Salvatore Macaluso (Trapani, Italy)
Salvatore Madonia (Palermo, Italy)Erasmo Miele (Naples, Italy)
Filippo Mocciaro (Palermo, Italy)Giuseppe Navarra (Messina, Italy)Ambrogio Orlando (Palermo, Italy)Emanuele Orlando (Palermo, Italy)
Claudio Papi (Rome, Italy)Gilberto Poggioli (Bologna, Italy)
Sara Renna (Palermo, Italy)Claudio Romano (Messina, Italy)Chiara Sapienza (Catania, Italy)Gaspare Solina (Palermo, Italy)Maurizio Vecchi (Milan, Italy)
Francesco Vitale (Palermo, Italy)
ECML’evento è stato accreditato dal Provider PLS Educational (3516-171808Ed. 1) per la professione del Medico Chirurgo nelle discipline di Gastroenterologia,
Chirurgia Generale, Medicina Interna, Pediatria, Pediatria di Libera Scelta. L’evento prevede l’assegnazione di 10 crediti formativi.
Venerdì 9 dicembre 2016
14.15-14.30 Greetings from the General Manager of “VILLA SOFIA-CERVELLO” Hospital
Ing. G. Venuti14.30-14.35 Introduction M. Cottone
A. Orlando C. Romano
SESSION IChairmen: M. Cottone, A. Orlando
14.35-15.00 Network on biologics in Sicily, advantages and limitations: up to date
M. Cottone15.00-15.15 Discussion15.15- 15.40 AIFA project on the safety
of immunosuppressive treatment: final results
A. Orlando15.40-16.00 Discussion
SESSION IIChairman: A. Craxi
16.00-16.15 Clinical case C. Sapienza16.15-16.40 Hepatitis B and C
virus infection and Immunosuppressive therapy in patients with IBD in children and adults
S. Madonia16.40-17.05 Is it CMV infection
a contraindication to immunosuppressive and biological therapy in children and adults?
V. Criscuoli17.05-17.30 Immunosuppressive
(thiopurines, methotrexate…) treatment related infections in adults
W. Fries17.30-17.55 Immunosuppressive
(thiopurines, methotrexate…) treatment related infections in children
C. Romano17.55-18.20 Biological treatment related
infections in children and adults
S. Renna18.20-18.45 Discussion
Safety of immunosuppressive treatment
in the management of Inflammatory
Bowel diseasePalermo, 9-10 dicembre 2016
This is the second edition of the congress held in December 2014 on the safety of the immunosuppressive
and biologics treatment in Inflammatory Bowel Disease (IBD).
In this edition the focus will also be given within pediatric and surgery fields.
Infections and malignancies are the major issues for clinicians in the management of patients with IBD
because of concerns about the safety of drugs currently used in treatment, including immunosuppressive
agents and tumor necrosis factor (TNF) antagonists. Infections are strongly associated with IBD both in
their etiopathogenesis and in their clinical course. A number of viral infections, tuberculosis and other
therapy-related infections create challenges for the successful management of intestinal disease with
immunosuppressive agents or TNF antagonists.
Recently published guidelines offer a strong support to deal with these issues.
Major concern about IBD patients with malignancies is related to the risk of maintaining
immunosuppressant or anti-TNF therapy also after the diagnosis of malignancy and the management of
a clinical relapse of IBD in patients with a recent diagnosis of malignancy. Further research is required to
optimize strategies for IBD patients with malignancies. At the moment, all therapeutic choice is made
on an individual basis, with an integrative multidisciplinary approach.
The congress will develop the best strategies for managing these issues and all the sessions will be
preceded by a clinical case coherent with the topics.
Finally, will present the results of the network on the treatment with biologics of the IBD in Sicily and
the final results of AIFA project on the safety of immunosuppressive treatment in IBD in our center.
II Congress
Sabato10 dicembre 2016
SESSION III Chairmen: E. Miele, M. Vecchi
08.30-08.45 Clinical case E. Orlando 08.45-09.10 Risk of Cancer in IBD
patients treated with biologics
L. Biancone 09.10-09.40 Risk of Cancer in
IBD patients treated with thiopurines and methotrexate and management in patients with Cancer history: updating
D. Laharie 09.40-10.10 Which is the safety profile
of new biological drugs? F. Mocciaro 10.10-10.45 Discussion 10.45-11.00 COFFEE BREAK
SESSION IV Chairmen: M. Cappello, P. Lionetti
11.00-11.15 Clinical case M. Citrano11.15-11.40 Biologics in early onset
Inflammatory Bowel Disease: indications and treatment related safety
M. Aloi11.40-12.05 Biologics in elderly:
indications and treatment related safety
M. Cottone12.05-12.20 Discussion
12.20-12.45 Immunosuppressive therapy in pregnancy and lactation in IBD patients
F. Castiglione12.45-13.10 Role of vaccines in
patients treated with immunosuppressants and biologics: updating
F. Vitale13.10 – 13.30 Paradoxical reactions
to biologics in patients with IBD
A. Armuzzi13.30-13.50 Discussion 13.50-15.00 LUNCH
SESSION V Chairmen: C. Cammà, G. Navarra
15.00-15.15 Clinical Case F.S. Macaluso15.15-15.45 Tandem Talk: Biological
treatment increases infectious complications related to surgery in Ulcerative Colitis?
P. Gionchetti, G. Poggioli15.45-16.05 Discussion16.05-16.35 Tandem Talk: Biological
treatment increases infectious complications related to surgery in Crohn’s Disease?
C. Papi, G. Solina16.35-16.50 Discussion 16.50-17.00 Closing remarks A. Orlando, C. Romano 17.00-17.20 CME completion